Health Care [ 7/12 ] | Pharmaceuticals [ 40/74 ]
NYSE | Common Stock
Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally.
The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD).
It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta.
The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology.
It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol.
Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jan 31, 25 | 1.98 Increased by +29.41% | 1.78 Increased by +11.44% |
| Oct 29, 24 | 2.06 Increased by +12.57% | 1.96 Increased by +5.10% |
| Jul 18, 24 | 1.97 Increased by +7.65% | 1.89 Increased by +4.23% |
| Apr 23, 24 | 1.80 Increased by +5.26% | 1.69 Increased by +6.51% |
| Jan 31, 24 | 1.53 Increased by +0.66% | 1.69 Decreased by -9.47% |
| Oct 24, 23 | 1.83 Increased by +15.82% | 1.70 Increased by +7.65% |
| Jul 19, 23 | 1.83 Increased by +17.31% | 1.68 Increased by +8.93% |
| Apr 25, 23 | 1.71 Increased by +17.12% | 1.55 Increased by +10.32% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 13.56 B Increased by +15.13% | 2.82 B Decreased by -66.77% | Increased by +20.78% Decreased by -71.14% |
| Sep 30, 24 | 13.17 B Increased by +8.93% | 3.19 B Increased by +81.09% | Increased by +24.21% Increased by +66.24% |
| Jun 30, 24 | 12.51 B Decreased by -10.22% | 3.25 B Increased by +40.16% | Increased by +25.94% Increased by +56.11% |
| Mar 31, 24 | 11.83 B Decreased by -10.44% | 2.69 B Increased by +17.23% | Increased by +22.72% Increased by +30.89% |
| Dec 31, 23 | 11.78 B Decreased by -10.02% | 8.48 B Increased by +478.44% | Increased by +72.01% Increased by +542.84% |
| Sep 30, 23 | 12.09 B Decreased by -5.84% | 1.76 B Increased by +11.95% | Increased by +14.56% Increased by +18.90% |
| Jun 30, 23 | 13.94 B Increased by +6.50% | 2.32 B Increased by +36.72% | Increased by +16.62% Increased by +28.37% |
| Mar 31, 23 | 13.21 B Increased by +3.07% | 2.29 B Increased by +3.20% | Increased by +17.36% Increased by +0.12% |